- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02491177
Mother and Infant Visit Adherence and Treatment Engagement Study (MOTIVATE!)
22. April 2021 aktualisiert von: University of Colorado, Denver
Maximizing Adherence and Retention for Women and Infants in the Context of Option B+
This is a 2x2 factorial cluster randomized trial of two interventions to improve retention and adherence for women and infants on Option B+.
The overall goal is to determine which intervention (or combination of interventions) maximizes antiretroviral therapy (ART) adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.The proposed study will be conducted in rural Nyanza Province, Kenya at 20 low-resource primary health care facilities and associated communities supported by Family AIDS Care and Education Services (FACES), a President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV prevention care, and treatment program, ((AIDS) acquired immune deficiency syndrome, (HIV) human immunodeficiency virus) .
The investigators will assess both process and outcome indicators using a 2x2 factorial design, in which equal numbers of clusters will be randomized to one of the interventions (community-based mentor mothers or theory-based mobile text messages), both interventions, or standard of care.
The interventions will be added to fully integrated high quality HIV and antenatal, maternal, neonatal, and child health (ANC/MNCH) services already offered at these sites.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
In order to eliminate new pediatric HIV infections, save maternal lives, and simplify antiretroviral therapy (ART) implementation in settings with generalized HIV epidemics, current World Health Organization (WHO) guidance recommends lifelong triple ART for all pregnant and breastfeeding women (Option B+).
However, despite the promise of Option B+ to remove logistical barriers and to promote maternal health through life-long ART, this strategy brings challenges.
Key amongst these challenges are adherence to ART and continuous retention in HIV care, especially for women who do not require ART for their own health.
Barriers to adherence and retention in care for prevention of mother-to-child transmission (PMTCT) have been identified at the individual, interpersonal, community, and health facility levels; yet specific barriers in the context of Option B+ are not well understood.
The investigators' study will be conducted at 20 health facilities and associated communities in Nyanza Province, Kenya where Mother to Child Transmission (MTCT) rates prior to Option B+ roll-out remained near 10%, despite the wide availability of PMTCT services.
As Option B+ is scaled up in Kenya, it is essential to identify effective methods to ensure long-term adherence and retention in care for mother-baby pairs, throughout pregnancy, breastfeeding, and beyond.
Building on the investigating team's prior research experience in this setting, the investigators propose to gain understanding of and address potential barriers at the individual, community, and health facility levels through formative research with HIV-positive pregnant and postpartum women, their male partners, and health care providers.
This information will be used to refine two proposed interventions that are highly likely to maximize ART adherence and retention in care among HIV-infected pregnant women and HIV-exposed infants.
These interventions will be rigorously tested in rural Kenya, using a cluster randomized 2x2 factorial design.
The evidence-based interventions to be tested will include 1) community Mentor Mothers (cMM) who will provide support for ART adherence and retention in care for HIV-positive women in the community and 2) individually tailored, theory based mobile phone text messages to help retain women and infants in HIV care.
The investigators' overall goal is to determine which intervention (or combination of interventions) maximizes ART adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.
The investigators' primary outcomes will include ART adherence at 12 months postpartum and retention in care, measured by a documented HIV care visit within 90 days prior to 12 months postpartum.
Secondary outcomes will include MTCT at 6 weeks, 12 months and 18 months; as well as maternal viral loads and CD4 counts.
Results from this study will inform the scale-up of Option B+ in Kenya by identifying effective interventions and combinations of interventions that can reduce barriers and increase facilitators of optimal ART adherence and retention in care with the aims of reaching the elimination of mother to child transmission of HIV and significantly improving maternal health.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
1338
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Nairobi, Kenia
- Kenya Medical Research Institute
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Weiblich
Beschreibung
Inclusion Criteria:
- Age 18 years or older,
- HIV-infected pregnant women and their HIV-exposed infants pairs,
- attends the antenatal care (ANC) clinic at one of the study sites.
Exclusion Criteria:
- Less than 18 years of age,
- HIV-infected women not currently pregnant,
- not HIV-infected at the time of the first ANC visit.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Fakultätszuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Sonstiges: cMM and Text Messaging
Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention.
The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
|
Home visits from community mentor mothers
Text messages received on mobile phone
|
|
Sonstiges: cMM Only
Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
|
Home visits from community mentor mothers
|
|
Sonstiges: Text Messaging Only
Participants randomized to this arm will receive the mobile phone text messaging intervention only.
The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
|
Text messages received on mobile phone
|
|
Kein Eingriff: Neither cMM nor Text Messaging
Participants randomized to this arm will receive standard of care with no interventions.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Self-reported adherence on antiretroviral therapy
Zeitfenster: 12 months post-partum
|
Self-report
|
12 months post-partum
|
|
Adherence on antiretroviral therapy
Zeitfenster: 12 months post-partum
|
Viral load<100 copies/ml based on medical records
|
12 months post-partum
|
|
Adherence on antiretroviral therapy (infant)
Zeitfenster: 12 months post-partum
|
Use of ARVs for the infant
|
12 months post-partum
|
|
Retention in care
Zeitfenster: 12 months post-partum
|
Proportion of women who have an HIV care visit within 90 days at 12 months after the birth
|
12 months post-partum
|
|
Adherence on antiretroviral therapy (dried blood spots)
Zeitfenster: 12 months post-partum
|
Viral load<100 copies/ml based on dried blood spots
|
12 months post-partum
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maternal CD4 count change
Zeitfenster: 6 months after baseline
|
Change in CD4 count baseline to 6 months after baseline
|
6 months after baseline
|
|
Maternal viral load count change
Zeitfenster: 6 months after baseline
|
Change in viral load from baseline to 6 months after baseline
|
6 months after baseline
|
|
Infant retention in care (feeding method)
Zeitfenster: 12 and 18 months
|
Infant feeding method
|
12 and 18 months
|
|
Infant retention in care
Zeitfenster: 12 and 18 months
|
Retention in care through 12 and 18 months
|
12 and 18 months
|
|
Infant retention in care (survival status)
Zeitfenster: 12 and 18 months
|
Survival status of infant
|
12 and 18 months
|
|
Uptake of intervention services (Number/types of text messages sent)
Zeitfenster: 3 years
|
Number/types of text messages sent
|
3 years
|
|
Uptake of intervention services (receipt of text messages)
Zeitfenster: 3 years
|
Receipt of text messages
|
3 years
|
|
Uptake of intervention services (home visits)
Zeitfenster: 3 years
|
Number of home visits received
|
3 years
|
|
Uptake of intervention services (support groups attended)
Zeitfenster: 3 years
|
Number of support groups attended.
|
3 years
|
|
Mother-to-Child-Transmission
Zeitfenster: 6 weeks, 9 months and 18 months
|
Result of infant HIV test at 6 wks, 9,18 months
|
6 weeks, 9 months and 18 months
|
|
Infant testing
Zeitfenster: 6 weeks, 9 months and 18 months
|
Uptake and date of infant testing
|
6 weeks, 9 months and 18 months
|
|
Infant enrollment in care
Zeitfenster: 6 weeks
|
Infant enrollment in HIV care
|
6 weeks
|
|
Male partner involvement
Zeitfenster: 12 months post-partum
|
Composite variable including Y/N response to indicate if male partner attended a health visit with his female partner, encouraged facility delivery, reminded to take HIV medication, reminded to go for HIV care, provided transport money to go to the clinic/dispensary, reminded to give the infant prophylaxis, helped giving the infant prophylaxis medication, collected medication for the woman or infant, encouraged specific infant feeding, and encouraged pediatric HIV testing.
These are assessed in the follow-up questionnaires completed at 12 months post-partum.
|
12 months post-partum
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Lisa Abuogi, MD, MSc, University of Colorado, Denver
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Palmer MJ, Henschke N, Bergman H, Villanueva G, Maayan N, Tamrat T, Mehl GL, Glenton C, Lewin S, Fonhus MS, Free C. Targeted client communication via mobile devices for improving maternal, neonatal, and child health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013679. doi: 10.1002/14651858.CD013679.
- Abuogi LL, Onono M, Odeny TA, Owuor K, Helova A, Hampanda K, Odwar T, Onyango D, McClure LA, Bukusi EA, Turan JM. Effects of behavioural interventions on postpartum retention and adherence among women with HIV on lifelong ART: the results of a cluster randomized trial in Kenya (the MOTIVATE trial). J Int AIDS Soc. 2022 Jan;25(1):e25852. doi: 10.1002/jia2.25852.
- Helova A, Onono M, Abuogi LL, Hampanda K, Owuor K, Odwar T, Krishna S, Odhiambo G, Odeny T, Turan JM. Experiences, perceptions and potential impact of community-based mentor mothers supporting pregnant and postpartum women with HIV in Kenya: a mixed-methods study. J Int AIDS Soc. 2021 Nov;24(11):e25843. doi: 10.1002/jia2.25843.
- Onono M, Odwar T, Wahome S, Helova A, Bukusi EA, Hampanda K, Turan J, Abuogi L. Behavioral Interventions can Mitigate Adverse Pregnancy Outcomes Among Women Conceiving on ART and Those Initiated on ART During Pregnancy: Findings From the MOTIVATE Trial in Southwestern Kenya. J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):46-55. doi: 10.1097/QAI.0000000000002521.
- Wanga I, Helova A, Abuogi LL, Bukusi EA, Nalwa W, Akama E, Odeny TA, Turan JM, Onono M. Acceptability of community-based mentor mothers to support HIV-positive pregnant women on antiretroviral treatment in western Kenya: a qualitative study. BMC Pregnancy Childbirth. 2019 Aug 13;19(1):288. doi: 10.1186/s12884-019-2419-z.
- Odeny TA, Onono M, Owuor K, Helova A, Wanga I, Bukusi EA, Turan JM, Abuogi LL. Maximizing adherence and retention for women living with HIV and their infants in Kenya (MOTIVATE! study): study protocol for a randomized controlled trial. Trials. 2018 Jan 29;19(1):77. doi: 10.1186/s13063-018-2464-3.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. Mai 2014
Primärer Abschluss (Tatsächlich)
1. April 2019
Studienabschluss (Tatsächlich)
1. März 2021
Studienanmeldedaten
Zuerst eingereicht
11. März 2015
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
2. Juli 2015
Zuerst gepostet (Schätzen)
7. Juli 2015
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
26. April 2021
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
22. April 2021
Zuletzt verifiziert
1. April 2021
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Aufbewahrung in der Pflege
- Säuglingsgesundheit
- Verbindung zur Pflege
- Vertikale Übertragung
- Frühkindliche Diagnose
- HIV-Übertragung
- Einhaltung der antiretroviralen Therapie
- Verhinderung der Mutter-Kind-Übertragung
- Community Mentor Mütter
- Mobile phone text messaging
- Maternale CD4/Viruslasten
- Akzeptanz von Eingriffen
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- Langsame Viruserkrankungen
- HIV-Infektionen
- Erworbenes Immunschwächesyndrom
Andere Studien-ID-Nummern
- 14-0331
- R01HD080477-01 (US NIH Stipendium/Vertrag)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Menschlicher Immunschwächevirus
-
Janssen-Cilag International NVAbgeschlossenInfektionen mit dem Human Immunodeficiency Virus (HIV). | Erworbenes Immunschwächesyndrom (AIDS)-VirusFrankreich, Vereinigtes Königreich, Belgien, Deutschland, Spanien, Schweiz, Dänemark, Israel, Österreich, Polen, Ungarn, Schweden, Irland
-
Merck Sharp & Dohme LLCZurückgezogenInfektionen mit dem Human Immunodeficiency Virus (HIV).
-
Johns Hopkins UniversityNational Institutes of Health (NIH)AbgeschlossenHuman Immunodeficiency Virus Positiv oder NegativVereinigte Staaten
-
Immuno Cure Holding (HK) LimitedThe University of Hong Kong; Immuno Cure 1 LimitedRekrutierungMenschlicher Immunschwächevirus | Human Immunodeficiency Virus I-InfektionHongkong
-
Merck Sharp & Dohme LLCAbgeschlossenInfektion mit dem Human Immunodeficiency Virus (HIV).Vereinigte Staaten, Deutschland
-
ViiV HealthcareGlaxoSmithKlineBeendetInfektion, Human Immunodeficiency Virus IVereinigte Staaten, Kanada, Puerto Rico
-
ViiV HealthcareGlaxoSmithKlineAbgeschlossen
-
ViiV HealthcareGlaxoSmithKline; ShionogiAbgeschlossenInfektion, Human Immunodeficiency Virus IVereinigte Staaten, Spanien, Deutschland, Australien, Kanada, Belgien, Dänemark, Niederlande, Vereinigtes Königreich, Frankreich, Italien, Rumänien
-
ViiV HealthcarePfizerAbgeschlossenInfektion mit dem Human Immunodeficiency Virus (HIV).Deutschland
-
Hospices Civils de LyonBeendetHuman Immunodeficiency Virus I-InfektionFrankreich
Klinische Studien zur cMM
-
NeuraLace Medical, Inc.AbgeschlossenNeuralgie | Neuropathischer Schmerz | Schmerzhafte diabetische NeuropathieVereinigte Staaten
-
NeuraLace Medical, Inc.Aktiv, nicht rekrutierendNeuropathischer Schmerz | Periphere NeuropathieVereinigte Staaten
-
Nevro CorpAktiv, nicht rekrutierendSchmerzhafte diabetische NeuropathieVereinigte Staaten
-
Presidio Medical, IncRekrutierungUltraniederfrequente Neuromodulation bei nozizeptiven chronischen Schmerzen im unteren RückenbereichNozizeptiver Schmerz | Axialer RückenschmerzAustralien
-
Nevro CorpAktiv, nicht rekrutierend
-
Vertos Medical, Inc.Aktiv, nicht rekrutierendSpinale Stenose, Lendengegend, mit neurogener ClaudicatioVereinigte Staaten
-
MedtronicNeuroSGX International LLCAbgeschlossenSchmerz, chronisch | Schmerz, hartnäckigSpanien, Niederlande, Belgien, Deutschland
-
Nevro CorpAktiv, nicht rekrutierendSchmerzhafte diabetische NeuropathieVereinigte Staaten
-
Wake Forest University Health SciencesBeendetSchmerzhafte diabetische NeuropathieVereinigte Staaten
-
University of MinnesotaMedica FoundationAbgeschlossenHypertonie | Diabetes | HyperlipidämieVereinigte Staaten